Companies: 10,795·Total market cap: $144.5T
4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc.

FDMTNASDAQHealthcare● Active
$8.64
$-1.37(-13.69%)
Market Cap$451666835
P/E Ratio—
52W High$12.34
52W Low$3.68
Overview

4D Molecular Therapeutics, Inc. (FDMT) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

FDMT · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$402.7M▼ -5.2% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$60.2M
cashAndCashEquivalents
Short-Term Investments
$342.4M
shortTermInvestments
YoY Change vs Prior Year
-5.2%
vs prior fiscal year
Latest Quarter
$390.9M
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$402.7MCash on Hand
Total Debt$21.4MTotal Debt
Net Cash / Net Debt+$381.2MNet Cash Position
Cash vs Debt Ratio
Cash 95%Debt 5%

4D Molecular Therapeutics, Inc. has a net cash position of $381.2M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$402.7M − $21.4M = +$381.2M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
FDMT annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$402.7M-5.2%
Dec 31, 2024$424.9M+47.4%
Dec 31, 2023$288.2M+35.0%
Dec 31, 2022$213.6M-13.8%
Dec 31, 2021$247.8M-10.5%
FDMT cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.8%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc.YOU
FDMT
$402.7M89.2%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

4D Molecular Therapeutics, Inc. (FDMT) cash on hand as of December 31, 2025 is $402.7M, comprising $60.2M in cash and cash equivalents (CCE) plus $342.4M in short-term investments — reported as 4D Molecular Therapeutics, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as 4D Molecular Therapeutics, Inc. cash reserves or cash position.

4D Molecular Therapeutics, Inc. annual cash on hand history shows decreased -5.2% in 2025: decreased -5.2% in 2025. 4D Molecular Therapeutics, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

4D Molecular Therapeutics, Inc. carries total debt of $21.4M against cash of $402.7M, resulting in a net cash position of +$381.2M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

FDMT cash on hand · 5 questions

As of December 31, 2025, 4D Molecular Therapeutics, Inc. (FDMT) has $402,655,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $60,241,000 in cash and cash equivalents (CCE) plus $342,414,000 in short-term investments. Latest quarter (March 31, 2026): $390,892,000. Data sourced from the annual 10-K filing via FMP.

FDMT cash on handFDMT cash reservesFDMT cash 2025how much cash does FDMT have

▸ Source: FMP /balance-sheet-statement · US GAAP · 4D Molecular Therapeutics, Inc. · 4D Molecular Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025